The Synaptic Corporation Announces Immediate Termination of Co-Branding and Distribution Relationship With Neurogenx Innovative Neurogenic Solutions Dba Neurogenx NerveCenters.

Neurogenx 4000PRO featuring S.E.A. Technology is discontinued by the patented holder and manufacturer.



Denver, CO - June 29, 2017 - (Newswire.com)

Today, The Synaptic Corporation announced immediate termination of its co-branding and distribution relationship with Neurogenx Innovative Neurogenic Solutions as of June 26, 2017, enabling owners of version Neurogenx 4000PRO featuring S.E.A. to immediately access to the original manufacturer's service and support through The Synaptic Corporation.

“We are proud of the value our technology has created by being the foundation of the Neurogenx NerveCenter, for the medical providers, their patients and for our shareholders,” said Chris Zueger, President and CEO of The Synaptic Corporation. “Taking a very streamlined approach, we began discussions on a possible continuation of the co-branding of our patented technology with Neurogenx Innovative Neurogenic Solutions; however, we were unable to reach terms that would have made sense for the Company and our shareholders. Instead, our focus will be on building strong relationships with the medical professionals utilizing our patented Neurogenx 4000PRO featuring S.E.A. Technology in their offices and NerveCenters. We see significant potential for Synaptic Electronic Activation Bio-Medical Instruments to expand further by offering attractive incentives to co-brand our newest technology. We feel that as the developer, designer and manufacturer, we create more tangible opportunities for returns for the medical provider over the moderate to long term.”

Many Neurogenx 4000Pro Providers have already benefited from partnering with The Synaptic Corporation. Building a relationship with the Neurogenx 4000PRO Providers will make available access to our manufacturer service and support and to the latest Synaptic Electronic Activation Bio-Medical Instruments. “The first screen that is seen when you turn the Neurogenx 4000PRO on reads Welcome to Synaptic Electronic Activation,” Said Kristin Zueger, VP of Sales of the Synaptic Corporation, “and I would like to personally extend that welcome to all Neurogenx NerveCenter Providers.”

​The Synaptic Corporation is focused on customer service driven by Neurogenx 4000PRO customer feedback and it is The Synaptic Corporation’s commitment to deliver the service, support and the latest product updates that our 4000PRO clientele are accustomed to. The Synaptic Corporation is available immediately to provide service and support, please visit us at www.synapticcorporation.com.

Founded in 1991, The Synaptic Corporation has proven to be a nationwide leader in Biomedical Technology. The company is the designer, developer, and patent holder of Synaptic Electronic Activation Bio-Medical Instruments including the Synaptic 4000PRO and the Neurogenx 4000PRO featuring S.E.A. Our Patented Neurogenx 4000PRO featuring S.E.A. technology is the foundation of the Neurogenx NerveCenters, as well as hundreds of S.E.A. providers across the U.S. The Synaptic Corporation’s mission is to develop, design and patent the latest and most state-of-the-art products and services designed to provide an effective non- invasive, drug-free way for people to live pain free.

Media Contact: 
Kristin Zueger​
800-685-7246
admin@synapticusa.com




Related Links
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=457323&lpcd=GZJ

Related Files
Synaptic SEA 4000 PRO Product Details.pdf
US Patents Granted Synaptic.pdf

Related Images




Press Release Service by Newswire.com

Original Source: The Synaptic Corporation Announces Immediate Termination of Co-Branding and Distribution Relationship With Neurogenx Innovative Neurogenic Solutions Dba Neurogenx NerveCenters.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.